- Home
- SGLY vs GRI Comparison
SGLY vs GRI Comparison
Compare SGLY & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- GRI
- Stock Information
- Founded
- SGLY 2001
- GRI 2018
- Country
- SGLY United States
- GRI United States
- Employees
- SGLY N/A
- GRI N/A
- Industry
- SGLY
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- GRI Health Care
- Exchange
- SGLY Nasdaq
- GRI Nasdaq
- Market Cap
- SGLY 3.9M
- GRI 3.2M
- IPO Year
- SGLY 2008
- GRI N/A
- Fundamental
- Price
- SGLY $1.03
- GRI $1.26
- Analyst Decision
- SGLY
- GRI Strong Buy
- Analyst Count
- SGLY 0
- GRI 2
- Target Price
- SGLY N/A
- GRI $22.00
- AVG Volume (30 Days)
- SGLY 67.2K
- GRI 112.3K
- Earning Date
- SGLY 08-26-2025
- GRI 08-13-2025
- Dividend Yield
- SGLY N/A
- GRI N/A
- EPS Growth
- SGLY N/A
- GRI N/A
- EPS
- SGLY N/A
- GRI N/A
- Revenue
- SGLY $2,172,036.00
- GRI N/A
- Revenue This Year
- SGLY N/A
- GRI N/A
- Revenue Next Year
- SGLY N/A
- GRI N/A
- P/E Ratio
- SGLY N/A
- GRI N/A
- Revenue Growth
- SGLY N/A
- GRI N/A
- 52 Week Low
- SGLY $0.54
- GRI $1.10
- 52 Week High
- SGLY $7.65
- GRI $43.69
- Technical
- Relative Strength Index (RSI)
- SGLY 51.57
- GRI 40.16
- Support Level
- SGLY $1.02
- GRI $1.28
- Resistance Level
- SGLY $1.16
- GRI $1.45
- Average True Range (ATR)
- SGLY 0.08
- GRI 0.11
- MACD
- SGLY -0.01
- GRI 0.03
- Stochastic Oscillator
- SGLY 50.00
- GRI 29.30
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.